Naim Alkhouri
Overview
Explore the profile of Naim Alkhouri including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
256
Citations
6510
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Alkhouri N, Charlton M, Gray M, Noureddin M
Expert Opin Investig Drugs
. 2025 Feb;
PMID: 40016997
Introduction: Glucagon-like peptide-1 receptor agonists (GLP-1RAs), and dual GLP-1/glucose-dependent insulinotropic peptide (GIP) or glucagon receptor agonists have emerged as promising agents to treat metabolic dysfunction-associated steatotic liver disease (MASLD)/metabolic dysfunction-associated...
2.
Harrison S, Alkhouri N, Ortiz-Lasanta G, Rudraraju M, Tai D, Wack K, et al.
J Hepatol
. 2025 Feb;
PMID: 39938653
Background & Aims: Via regulation of glycaemic control and inflammation, free fatty receptor (FFAR)1 and 4 are potential targets for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). In this study,...
3.
Daniels S, Nelander K, Eriksson J, Jermutus L, Saillard J, Oyesola S, et al.
Contemp Clin Trials Commun
. 2025 Feb;
44:101437.
PMID: 39916681
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a common chronic liver disease that is heterogenous in nature with various drivers and modifiers such as metabolic dysfunction and genetic factors. MASLD...
4.
Aminian A, Aljabri A, Wang S, Bena J, Allende D, Rosen H, et al.
Nat Med
. 2025 Jan;
PMID: 39870816
No therapy has been shown to reduce the risk of major adverse liver outcomes (MALO) in patients with cirrhosis due to metabolic dysfunction-associated steatohepatitis (MASH). The Surgical Procedures Eliminate Compensated...
5.
Le P, Tatar M, Dasarathy S, Alkhouri N, Herman W, Taksler G, et al.
JAMA Netw Open
. 2025 Jan;
8(1):e2454707.
PMID: 39821400
Importance: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common cause of chronic liver disease and is projected to become the leading indication for liver transplant (LT) in the...
6.
Kaya E, Yilmaz Y, Alkhouri N
Expert Opin Investig Drugs
. 2024 Dec;
33(12):1167-1176.
PMID: 39663847
Introduction: Glucagon-like peptide-1 receptor (GLP-1 R) agonists have demonstrated remarkable effectiveness in the treatment of obesity and type 2 diabetes. Although these agents provide beneficial effects for metabolic dysfunction-associated steatohepatitis...
7.
Alkhouri N, Noureddin M
Am J Manag Care
. 2024 Nov;
30(9 Suppl):S159-S174.
PMID: 39513734
Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by hepatic steatosis that is confirmed by imaging or histology in the setting of at least 1 metabolic risk factor in the...
8.
Diaz L, Lazarus J, Fuentes-Lopez E, Idalsoaga F, Ayares G, Desaleng H, et al.
Commun Med (Lond)
. 2024 Oct;
4(1):219.
PMID: 39472739
Introduction: The 2023 nomenclature defined criteria for steatotic liver disease (SLD), including metabolic dysfunction-associated SLD (MASLD), alcohol-associated liver disease (ALD), and the overlapping MASLD/ALD (MetALD). We aimed to assess racial...
9.
Alkhouri N, Beyer C, Shumbayawonda E, Andersson A, Yale K, Rolph T, et al.
J Hepatol
. 2024 Sep;
82(3):438-445.
PMID: 39326675
Background & Aims: MRI biomarkers of liver disease are robust and reproducible alternatives to liver biopsy. Emerging data suggest that absolute reduction in iron-corrected T1 (cT1) of ≥80 ms and...
10.
Beyer C, Andersson A, Shumbayawonda E, Alkouri N, Alkhouri N, Banerjee A, et al.
J Magn Reson Imaging
. 2024 Sep;
61(4):1947-1955.
PMID: 39319470
Background: Quantitative magnetic resonance imaging metrics iron-corrected T1 (cT1) and liver fat from proton density fat-fraction (PDFF) are both commonly used as noninvasive biomarkers for metabolic dysfunction-associated steatohepatitis (MASH); however,...